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Abstract 40 
Sleep deprivation impairs cognitive performance and reliably alters brain activation in 41 
wakefulness and sleep. Nevertheless, the molecular regulators of prolonged wakefulness remain 42 
poorly understood. Evidence from genetic, behavioral, pharmacologic and imaging studies suggest 43 
that dopaminergic signaling contributes to the behavioral and electroencephalographic (EEG) 44 
consequences of sleep loss, although direct human evidence thereof is missing. We tested whether 45 
dopamine neurotransmission regulate sustained attention and evolution of EEG power during 46 
prolonged wakefulness. Here, we studied the effects of functional genetic variation in the dopamine 47 
transporter (DAT1) and the dopamine D2 receptor (DRD2) genes, on psychomotor performance and 48 
standardized waking EEG oscillations during 40 hours of wakefulness in 64 to 82 healthy volunteers. 49 
Sleep deprivation consistently enhanced sleepiness, lapses of attention and the theta-to-alpha 50 
power ratio (TAR) in the waking EEG. Importantly, DAT1 and DRD2 genotypes distinctly modulated 51 
sleep loss-induced changes in subjective sleepiness, PVT lapses and TAR, according to inverted U-52 
shaped relationships. Together, the data suggest that genetically determined differences in DAT1 53 
and DRD2 expression modulate functional consequences of sleep deprivation, supporting the 54 
hypothesis that striato-thalamo-cortical dopaminergic pathways modulate the neurobehavioral and 55 
neurophysiological consequences of sleep loss in humans. 56 
  57 
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Introduction 58 
Sleep deprivation enhances sleepiness, impairs performance and alters electrical brain 59 
activity in a highly predictable fashion1–4. Modern lifestyle means that these sleep-loss related 60 
cognitive deficits have developed to a public health concern. In the laboratory, neurobehavioral 61 
deficits of sleep deprivation are accurately indexed by lapses of attention  on the psychomotor 62 
vigilance task (PVT), which is considered a gold-standard measurement of sustained vigilant 63 
attention3,5. Neurophysiological consequences of sleep loss on the other hand, are reflected by 64 
distinct oscillations in the waking electroencephalogram (EEG)6,7. Importantly, these neurobehavioral 65 
and neurophysiological consequences vary widely among individuals. Ample evidence now 66 
demonstrates that genetic influences strongly modulate waking EEG oscillations and alters PVT 67 
lapses across prolonged waking, even within consecutive test sessions8–12. Consistent with a genetic 68 
contribution, the impact of sleep loss on distinct subjective, PVT, and neurophysiological markers of 69 
alertness, is trait-like and highly robust within individuals. Intriguingly, however, these variables 70 
don’t typically show a clear association with each other, but rather develop seemingly 71 
independently13,14. Here, we hypothesized that functional variation in genes impacting local 72 
dopaminergic neurotransmission affects sleep loss-induced changes in PVT lapses and the waking 73 
EEG along a similar trajectory. 74 
The neurotransmitter dopamine contributes to the regulation of different brain functions, 75 
including sustained attention15 and EEG oscillations during wakefulness16,17. Wakefulness-promoting 76 
medications typically enhance dopaminergic neurotransmission and improve performance on the 77 
PVT during simulated night shifts and after sleep deprivation18–20. Nevertheless, a distinct role for 78 
dopamine in the proper regulation of sleep wake-states has long been controversial21. Intriguing 79 
recent data obtained with chemogenetic and optogenetic methods in flies and mice have started to 80 
change this view22–24. Moreover, genetically modified animals lacking a functional dopamine re-81 
uptake transporter (DAT) exhibit prolonged wakefulness and shortened sleep25–29. In humans, a 82 
variable-number-tandem-repeat (VNTR) polymorphism (SNP-ID: rs28363170) of the gene encoding 83 
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DAT (SLC6A3 or DAT1) modulates individual effects of sleep loss on sleep rebound and sensitivity to 84 
caffeine, as well as rewards and punishments30,31. Homozygous ten-repeat allele (10R/10R) carriers 85 
of this polymorphism presumably have 15-20% reduced DAT protein expression compared to nine-86 
repeat (9R) allele carriers32,33. Compared to the 9R carriers, 10R/10R homozygotes exhibits a clearly 87 
and more pronounced increase in sleep intensity after extended waking (as measured by EEG slow-88 
wave activity [SWA] in non-rapid-eye-movement [NREM] sleep)30. This measure is the best 89 
established biomarker of increased sleep need after sleep loss34. 90 
Dopamine D2 receptors were recently proposed to be particularly important for sleep-wake 91 
regulation35,36. Nevertheless, the exact role of D2 receptor agonist and antagonists in modulating 92 
behavioral states remain controversial37. Alike DAT, these receptors are primarily expressed in the 93 
striatum. Common variants of the gene (DRD2) encoding the D2 receptor in humans influence 94 
reported habitual sleep duration38. Molecular imaging studies revealed that sleep deprivation 95 
reduces D2 receptor availability in the striatum39–41, and suggest that these receptors are involved in 96 
modulating visual attention in rested wakefulness and after sleep deprivation42. The DRD2 gene 97 
includes a functional 957C>T single nucleotide polymorphism (SNP-ID: rs6277) that affects levels and 98 
stability of mRNA and has been associated with 15-20% enhanced striatal D2 receptor availability in 99 
C-allele carriers compared to T-allele carriers43. Importantly, functional interactions between DAT1 100 
and DRD2 genes44,45 appear to modulate dopamine-dependent neuronal activity according to an 101 
inverse U-shaped relationship46. 102 
Based on the evidence presented above, we aimed at investigating the impacts of functional 103 
DAT1 and DRD2 polymorphisms on sleep deprivation-induced changes in subjective sleepiness, 104 
attentional lapses and the waking EEG in humans. We hypothesized that these genetic variants 105 
impact individual consequences of sleep loss and expected that they interact to modulate vigilant 106 
attention and EEG power during prolonged wakefulness according to U-shaped relationships. 107 
 108 
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Results 109 
The impact of sleep deprivation on PVT performance and EEG oscillations are likely governed by 110 
separate mechanisms 111 
To assess the consequences of sleep deprivation, performance on the PVT, subjective 112 
sleepiness and the waking EEG were quantified in 14 equally-spaced sessions across the 40 hours of 113 
prolonged wakefulness. From the baseline to the sleep deprivation day, PVT performance 114 
deteriorated (factor ‘day’: lapse frequency: ηp2 = 0.312; response variability: ηp2 = 0.109), whereas 115 
the sleepiness score increased (ηp2 = 0.805; 2.43 ± 0.08 vs. 4.67 ± 0.09) (Fig. 1A-D; for detailed 116 
statistics, see Supplementary Table 1). These changes revealed a tight association (rs2 = 0.110, p < 117 
0.008, n = 64). Failed responses also increased with time on task within PVT sessions (ηp2 = 0.212), 118 
and this increase was amplified by sleep deprivation (‘day’ x ‘time on task’: ηp2 = 0.157). By contrast, 119 
response variability was virtually unaffected by time on task (ηp2 = 0.011). Significant interactions 120 
between ‘day’ and ‘clock time’ were observed for both neurobehavioral performance (lapse 121 
frequency: ηp2 = 0.083; response variability: ηp2 = 0.017) and sleepiness (ηp2 = 0.135), confirming 122 
that these state variables not only depend on sleep-wake history but also on diurnal fluctuations. 123 
Because it was previously concluded that the behavioral consequences of sleep deprivation 124 
can dissociate from neurophysiological indices of elevated sleep pressure47, the evolution of 125 
electrical brain activity in five predefined frequency bands and the theta-to-alpha ratio (TAR) was 126 
quantified at 3-hour intervals across prolonged wakefulness. By determining the TAR, the signal to 127 
noise ratio (SNR) between-subjects (TAR: 1.76 ± 0.10) was enhanced compared to the theta (1.17 ± 128 
0.20; t13 = -10.43, p < 0.0001) and alpha frequency bands (1.06 ± 0.08; t13 = -17.2, p < 0.0001), which 129 
improved the capability to detect genotype-dependent differences (see below). By contrast, within-130 
subject SNR was only slightly reduced (TAR: 4.25 ± 2.13; theta: 4.55 ± 2.01; alpha: 4.83 ± 2.09; TAR 131 
vs. theta: t80 = 1.22, p > 0.22; TAR vs. alpha t80 = 2.11, p < 0.04).  132 
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Sleep deprivation increased theta activity (‘day’: ηp2 = 0.548) and TAR (ηp2 = 0.519), while 133 
alpha activity was unaffected (ηp2 = 0.011, Fig. 1E-G, Supplementary Table 1). On the other hand, 134 
time of day affected theta (‘clock time’: ηp2 = 0.062; ‘clock time’ x ‘day’: ηp2 = 0.075) and alpha 135 
activity (‘clock time’: ηp2 = 0.067; ‘clock time’ x ‘day’: ηp2 = 0.049), and also tended to modulate TAR 136 
(‘clock time’: ηp2 = 0.017; ‘clock time’ x ‘day’: ηp2 = 0.015). Consistent with the literature, the sleep 137 
deprivation induced changes in theta power and TAR were not associated with increased PVT lapse 138 
frequency (rall < 0.076, pall > 0.55), suggesting that these markers are governed by separate 139 
mechanisms. 140 
 141 
DAT1 and DRD2 genotypes affect PVT performance and subjective sleepiness 142 
In the next step, the effects of the functional polymorphisms rs28363170 (‘DAT1’), rs6277 143 
(‘DRD2’) and their combination (‘DAT1-DRD2 combined’) on the evolution of PVT performance 144 
during prolonged wakefulness were investigated. The p-values of all ANOVA’s investigating genetic 145 
effects were corrected for by multiple comparison using false discovery rate (FDR) correction (see 146 
Supplementary Table 2).  147 
When PVT response speed was considered, complex interactions between the genotypes, 148 
sleep deprivation and diurnal rhythmicity were observed (‘DAT1’ x ‘clock time’ x ‘day’: ηp2 = 0.020; 149 
‘DAT1-DRD2 combined’ x ‘clock time’ x ‘day’: ηp2 = 0.066). When investigating the sleep-deprivation 150 
induced change in PVT lapses, a significant modulation by the ‘DRD2’ genotype was observed, yet 151 
with a minuscule effect size (ηp2 = 0.008). When ‘DAT1’ and ‘DRD2’ genotypes were combined, 152 
however, much larger effect sizes could be identified. The statistical analyses demonstrated a main 153 
effect of genotype (‘DAT1-DRD2 combined’: ηp2 = 0.156), as well as interactions with time awake and 154 
clock time (‘DAT1-DRD2 combined’ x ‘clock time’: ηp2 = 0.080; ‘DAT1-DRD2 combined’ x ‘day’: ηp2 = 155 
0.055; ‘DAT1-DRD2’ x ‘clock time’ x ‘day’: ηp2 = 0.080) (Fig. 2 and supplementary figure 1). Post hoc 156 
testing revealed no significant differences at baseline (day 1), yet multiple significant effects on day 2 157 
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after sleep deprivation (Fig. 2B-C). These findings show that the 10R/10R-C/T and 9R-C/C genotypes 158 
had significantly fewer lapses after sleep deprivation than the remaining four DAT1-DRD2 genotypes. 159 
Taken together, these results indicate that the DAT1-DRD2 10R/10R-C/T and 9R-C/C genotypes 160 
maybe more resilient to deteriorating psychomotor vigilance by sleep deprivation (Fig. 2A and 161 
Supplementary figure 1). It also should be noted, that the U-shaped relationship observed on day 2 162 
for PVT lapse frequency, closely mirrored the relative increase in PVT lapses after sleep deprivation 163 
(Supplementary figure 1B). 164 
Similar to PVT performance, the increase in subjective sleepiness by sleep deprivation was 165 
not modulated by DAT1 and DRD2 genotypes alone, yet by the combined DAT1-DRD2 genotypes 166 
(‘DAT1-DRD2 combined’ x ‘day’: ηp2 = 0.080). Intriguingly, the increase in subjective sleepiness 167 
resembled a similar U-shaped relationship, split by DAT1 genotype (Fig. 2D). 168 
 169 
DAT1 and DRD2 genotypes affect the waking EEG during prolonged wakefulness 170 
Next, it was investigated whether the dopaminergic genotypes also influence waking EEG 171 
oscillations during prolonged wakefulness. Three-way ANOVAs revealed no effects of ‘genotype’, or 172 
their interaction, on the evolution of delta, theta, low-beta and high-beta frequency activity during 173 
prolonged waking (see Supplementary Table 2 for statistics). By contrast, DAT1 (‘DAT1’ x ‘day’: ηp2 = 174 
0.059) and DAT1-DRD2 combined genotypes (‘DAT1-DRD2 combined’ x ‘day’: ηp2 = 0.109) affected 175 
the change in alpha activity by sleep deprivation. Similarly, DAT1 (‘DAT1’ x ‘day’: ηp2 = 0.049), DRD2 176 
(‘DRD2’ x ‘day’: ηp2 = 0.071) and DAT1-DRD2 combined genotypes (‘DAT1-DRD2 combined’ x ‘day’: 177 
ηp2 = 0.137) modulated TAR (Fig. 3). Specifically, the percentage increase in TAR after sleep 178 
deprivation was blunted in DAT1 9R-allele carriers when compared to DAT1 10R/10R homozygotes 179 
(Fig. 3A) and in DRD2 C/T heterozygotes compared to C/C homozygotes (Fig. 3B).  180 
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Similar to PVT lapses, the increase in TAR after sleep deprivation may be described by a U-181 
shaped relationship, split by DAT1 genotype (Fig. 3C). Intriguingly, however, whereas the curve 182 
associated with DAT1 10R/10R was reminiscent of the sleep deprivation-induced consequences on 183 
sleepiness and neurobehavioral performance, the curve associated with the DAT1 9R genotype 184 
appeared inverted.  185 
 186 
Discussion 187 
Modulation of dopaminergic neurotransmission in Drosophila and mouse mutants are 188 
associated with profound modulations of wakefulness and sleep26–29. Recent chemogenetic and 189 
optogenetic studies in flies and mice confirmed this crucial role of dopamine in regulating sleep-190 
wake behaviors22–24. Nevertheless, the contribution of the dopaminergic system to sleep-wake 191 
regulation in humans is still only poorly described. The present study revealed that functional 192 
polymorphisms of DAT1 and DRD2 together modulate the neurobehavioral, subjective and 193 
neurophysiological consequences of sleep deprivation. Nevertheless, the distinct contributions of 194 
DAT1 and DRD2 genotypes to wakefulness-induced changes in physiological fatigue and sustained 195 
attention on one hand48,49, and EEG-derived markers of vigilance on the other hand6,7,50 appear to 196 
differ. 197 
The relationships between dopaminergic neurotransmission and brain functions are 198 
complex. They are task specific and depend on the different dopamine receptor families and 199 
dopaminergic pathways involved51,52. Furthermore, epistasis between genetic variants of DAT1 and 200 
DRD2 genes has been described44. Functional magnetic resonance imaging data suggested that 201 
activation of the striatum in a monetary reward paradigm depends on genetic variants of both DAT1 202 
and DRD2 genes. Indeed, Li et. al. showed in more than 1200 healthy adults of European decent that 203 
individuals with elevated levels of dopaminergic transmission, associated with DAT1 9R and DRD2 204 
C/C genotypes, showed better performance on a serial memory task than individuals with lower 205 
 9 
dopaminergic transmission45. Similarly, activation of the prefrontal cortex during a working memory 206 
and recognition task could be described by a U-shaped relationship depending on functional variants 207 
of DAT1 and DR2D genes modifying dopaminergic neurotransmission46. Consistent with these data, 208 
we found that increased lapse frequency on the PVT, subjective sleepiness, and EEG TAR after sleep 209 
deprivation can be described by U-shaped curves split by DAT1 genotype. The curves reflecting PVT 210 
performance and subjective sleepiness were similar, suggesting that the observed effects may 211 
reflect inherent consequences of sleep deprivation. This is intriguing, especially when considering 212 
that the sample sizes differed by 20% (between 64 and 80 individuals) for PVT recordings and 213 
subjective sleepiness ratings. Considering PVT lapse frequency, our data suggests that subjects 214 
carrying the DAT1-DRD2 10R/10R-C/T or the DAT1-DRD2 9R-C/T genotypes, are more resilient to 215 
sleep deprivation than the remaining four genotypes. When inspecting the increase in subjective 216 
sleepiness, however, the DAT1-DRD2 9R-C/C genotype is significantly less affected by prolonged 217 
wakefulness than the DAT1-DRD2 10R/10R-T/T and 9R-C/T genotypes. These effects could not be 218 
attributed to either the DAT1 or the DRD2 genotypes alone, and show that genotype dependent 219 
discrepancies between subjective and objective markers of sleep loss are present.  220 
The statistical analyses revealed that the combined effects of DAT1 and DRD2 genotypes 221 
explained about 8% of the observed variability in subjective sleepiness, 15% in PVT lapse frequency, 222 
and 13% in EEG TAR. The magnitude of these effect sizes can be considered moderate to large53,54. 223 
They appear considerably larger than what was previously reported for other genetic variants11, 224 
which emphasizes the robustness of the findings. The direction by which the DAT1 and DRD2 225 
genotypes modulated sustained attention and subjective sleepiness after sleep deprivation should 226 
also be noted (Fig. 2). Interestingly, the effect of the DRD2 genotypes was almost inverted in 227 
10R/10R homozygotes and 9R allele carriers of DAT1. The different relationships highlight the 228 
importance of considering related signaling pathway components, rather than single genetic 229 
variants, when examining possible genetic influences on the vulnerability to sleep deprivation. 230 
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Future studies may investigate the relative quantitative contributions of DAT and D2 protein 231 
expression on neurobehavioral and neurophysiological consequences of sleep deprivation.  232 
Not only the neurobehavioral consequences of sleep deprivation, but also those of ‘time-on-233 
task’ in rested and sleep deprived subjects were associated with common genetic variants55. Lim and 234 
colleagues investigated the impact of six polymorphisms related to dopaminergic neurotransmission 235 
on time-on-task-dependent decrements in PVT performance in 350 adults in the absence of sleep 236 
deprivation12. The authors concluded that the VNTR in DAT1, but not the ANKK1 polymorphism of 237 
DRD2 (SNP-id: rs1800497), modulated the decline in reaction speed associated with increasing task 238 
duration. Although both lapse frequency and response variability increased with time-on-task, our 239 
repeated measure analyses did not corroborate a DAT1 genotype-dependent modulation. Further 240 
studies are needed to explore whether the discrepancy reflects differences in study design or 241 
reduced power because of the smaller sample size in the present study. 242 
Previous work stressed the lack of clear associations between PVT performance, sleepiness 243 
and neurophysiological markers of vigilance13,14,47,56. Our analyses corroborate these discrepancies, 244 
but only when the 9R-allele carriers of the DAT1 gene are considered. In 10R/10R homozygotes, the 245 
suggested U-shaped relationships between DRD2 genotypes and increased lapse frequency, 246 
subjective sleepiness, and EEG TAR after sleep deprivation were remarkably similar. Given the lack of 247 
association between increased lapse frequency and theta activity or TAR, however, the genotypes 248 
may independently affect behavioral and EEG measures. This implies that they are likely governed by 249 
separate mechanisms, which are influenced by dopaminergic neurotransmission. 250 
The present study indicates that TAR may be a promising novel physiological marker of 251 
reduced vigilance associated with sleep deprivation. Indeed, work investigating the action of  252 
adrenergic and dopaminergic compounds on the multiple sleep latency test suggested that changes 253 
in TAR may predict vigilance6. In addition, based on comparisons of 85 electrophysiological EEG 254 
measures in 20 healthy adults it was concluded that the TAR is the best EEG marker to predict 255 
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changes in vigilance from wakefulness to sleep, and from wakefulness to superficial stage 1 sleep50. 256 
As reported here, the TAR enhanced between-subjects signal-to-noise-ratio when compared to 257 
either alpha or theta activity alone. Furthermore, the TAR showed a robust increase with sleep 258 
deprivation. Especially the impact of DAT1 genotype on increased TAR after sleep deprivation should 259 
be highlighted. Previous findings of our group revealed that homozygous 10R/10R carriers exhibited 260 
a more pronounced increase than 9R-allele carriers in nocturnal slow wave sleep and EEG slow-wave 261 
activity after prolonged wakefulness, suggesting that 10R/10R homozygotes show a more 262 
pronounced homeostatic response to sleep loss30. The data presented here support this notion and 263 
show that 10R/10R homozygotes of DAT1 display a stronger increase in TAR by sleep deprivation. 264 
Moreover, the data also reveal that DRD2 C/C homozygotes show a stronger increase in TAR after 265 
sleep-loss than the C/T heterozygotes, which suggests that also the DRD2 polymorphism is involved 266 
in homeostatic sleep-wake regulation. Nocturnal sleep EEG recordings before and after sleep 267 
deprivation are needed to further corroborate these findings.  268 
The DAT and dopamine D2 receptors are primarily expressed in the striatum. This brain 269 
region may be an important part of the intrinsic system that controls sleep and wakefulness35,36. The 270 
present genetic findings support data collected in animals24–28,57 and observations from brain 271 
imaging30,39,40,42 and epidemiological38 studies in humans, suggesting prominent roles for DAT and D2 272 
receptors in sleep-wake regulation. They highlight the importance of the striatum in regulating 273 
changes in vigilant attention, subjective sleepiness, and neurophysiological EEG oscillations during 274 
prolonged wakefulness. The observed discrepancies between neurobehavioral and 275 
neurophysiological data point to an influence of the dopaminergic system in sleep-wake regulation, 276 
which is independent from motivational aspects35. It is likely that striatal dopaminergic signaling, 277 
together with the prefrontal cortex and related brain neurotransmitter and neuromodulator 278 
systems, contributes to the control of the sleep-wake continuum58. The data presented here suggest 279 
that common functional genetic variants linked to altered striatal dopaminergic neurotransmission  280 
contribute to individual neurobehavioral consequences of sleep loss. These genetic variants may 281 
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help define trait-like risks for sleep deprivation-related motor vehicle- and work-related accidents. 282 
Moreover, the genetic variants could explain individual differences in the efficacy of 283 
psychostimulants used to mitigate the detrimental effects of sleep-wake disorders and sleep 284 
deprivation. 285 
 286 
Methods 287 
Study participants and sleep deprivation protocol  288 
Eighty-two healthy right-handed volunteers (12 females) between 19 and 35 years 289 
completed the sleep deprivation experiment (see references: 30,59, for further details on the study 290 
protocols). All volunteers reported to be good sleepers, adhere to regular bedtimes, be in good 291 
physical health, and have no history of neurological or psychiatric disorders. Two months prior to 292 
enrollment, subjects did not consume any medication or illicit drugs, did not pass through time 293 
zones and consumed only moderate amounts of caffeine and alcohol. Three participants were 294 
moderate smokers (< 10 cigarettes per day). Good sleep quality (no undiagnosed sleep disorders) 295 
and efficiency (> 85%) were confirmed in a screening night in the sleep laboratory prior to study 296 
inclusion. At least three days before study initiation, participants were instructed to wear a wrist 297 
activity monitor on their non-dominant arm, fill in a sleep-wake diary, refrain from caffeine and 298 
alcohol, and strictly maintain 8 hours’ time in bed, corresponding to the scheduled bedtimes of the 299 
study. 300 
All participants completed 40 hours of constantly supervised wakefulness, preceded by two 301 
consecutive 8-hour sleep episodes in the sleep laboratory (adaptation and baseline nights). During 302 
prolonged waking, the consequences of sleep loss were monitored at 3 hour intervals with 303 
standardized test sessions, including subjective sleepiness ratings, PVT and waking EEG recordings. 304 
The study protocols were approved by the ethics committee of the Canton of Zürich for 305 
research on human subjects. Written informed consent was obtained from all participants prior to 306 
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the experiments, as required according to the principles in the Declaration of Helsinki. All subjects 307 
received financial compensation for their participation.  308 
 309 
Genotyping 310 
Genomic DNA was extracted from 3 ml fresh EDTA-blood (Wizard® Genomic DNA Purification Kit, 311 
Promega, Madison, WI). The rs28363170 polymorphism of DAT1 was determined by allele-specific 312 
PCR on an MJ Research PTC-225 thermal cycler (MJ Research/Bio-Rad, Reno, NV) at an annealing 313 
temperature of 67°C. Forward primer, 5’-tgtggtgtagggaacggcctga-3’, and reverse primer, 5’-314 
cttcctggaggtcacggctcaa-3’, with HOT FIREPol® DNA Polymerase was used. The 430-480 bp PCR 315 
products were analyzed by agarose gel electrophoresis. The functional polymorphisms rs6277 of 316 
DRD2 was determined using a Taqman® SNP Genotyping Assay (Life Technologies Europe B.V.; probe 317 
number: C__11339240_10). Allelic discrimination analysis was performed with SDS v2.2.2 software 318 
(Applied Biosystems, Foster City, CA, USA). All genotypes were replicated at least once for 319 
independent confirmation of results. The DRD2 genotype of one individual is lacking due to missing 320 
genetic material. Comparisons of demographic variables between DAT1 and DRD2 genotypes 321 
included weight, height, body mass index (BMI), age, gender, habitual alcohol and caffeine 322 
consumption, self-reported daily sleep duration, daytime sleepiness and trait anxiety (Table 1). No 323 
variable revealed a difference between the genotypes. Fishers exact test revealed that the DRD2 and 324 
DAT1 genetic groups were similarly distributed, both in the full (n = 81, p > 0.39) and in the 325 
subsample (n = 64; p > 0.30). 326 
Psychomotor vigilance task (PVT) and subjective sleepiness 327 
Vigilant attention during sleep deprivation was assessed by a PC-implemented e-Prime 328 
version (Psychology Software Tools Inc., Pittsburgh, PA) of the psychomotor vigilance task60. 329 
Eighteen individuals were excluded from the analyses because they performed a different, non-330 
computerized version of the task, resulting in a sample size of 64 subjects for the PVT task analyses. 331 
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The PVT is a simple reaction time task. When a digital millisecond counter starts to scroll in 332 
the center of the computer screen, subjects have to press a button with their right index finger on a 333 
response box (standardized keyboard) connected to the PC. Subjects received oral instructions and 334 
performed one training session on the evening prior to the baseline night. For each PVT trial, 100 335 
stimuli were presented (random inter-stimulus intervals: 2-10 s). To assess performance as a 336 
function of ‘time on task’ (TOT), the task was divided into five quintiles of 20 trials. Two extensively 337 
validated PVT variables were quantified48,56,61,62: ‘lapses of attention’ (defined as the number of trials 338 
with reaction times longer than 500 ms) and ‘standard deviation of response speed’ (calculated 339 
based on inverse reaction times and referred to as response variability). Both these variables are 340 
prominent markers of sleep loss and sensitive to TOT. 341 
Immediately prior to all PVT assessments, a validated German version of the Stanford 342 
Sleepiness Scale was administered63. The sleepiness ratings of all 82 subjects were included in the 343 
analyses.  344 
 345 
Waking EEG recordings 346 
At 3-hour intervals throughout prolonged wakefulness, standardized waking EEG recordings 347 
with polygraphic PSA24 (Braintronics Inc., Almere, The Netherlands) (n = 18; see: 2) or Artisan 348 
(Micromed, Mogliano Veneto, Italy) (n=64; see e.g.: 64) amplifiers were performed. The EEG data 349 
recorded with PSA24 amplifiers, were analogue band-pass filtered (-3 dB at 0.16 Hz; -3 dB at 102Hz) 350 
and sampled at 512 Hz, then digitally low-pass filtered (-3 dB at 49 Hz) and stored with a resolution 351 
of 128 Hz. The EEG data recorded with Artisan amplifiers, were analogue band-pass filtered (-3 dB at 352 
0.15 Hz; -3 dB at 67.2 Hz), sampled, and stored with a resolution of 256 Hz. Note that DAT1 and 353 
DRD2 genotypes were similarly distributed between PSA24 and Artisan amplifiers (pall > 0.87, Fishers 354 
exact test). The standard EEG derivation for sleep state scoring, C3A2, was analyzed. 355 
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At least 1 hour before each recording, subjects were confined to the sleep-laboratory 356 
(constant temperature: 19-21 °C; light intensity: < 150 lux). Fifteen minutes before each recording, 357 
subjects stayed in their own private bedroom. The recordings consisted of an initial 3-min recording 358 
period with eyes closed, followed by a 5-min period with eyes open, while fixating a black dot on the 359 
wall. During all recordings, study participants comfortably relaxed in a chair, and placed their chin on 360 
an individually adjusted chinrest. Artifacts were visually identified and excluded. Due to a technical 361 
problem, the data of one subject needed to be excluded. The power spectra of artifact-free, 2-s EEG 362 
epochs (50 % overlap, Hanning window, frequency resolution 0.5 Hz) recorded with eyes open were 363 
computed and analyzed between 0 - 30 Hz. 364 
To investigate changes in the waking EEG across prolonged time awake, spectral power in 365 
the standard EEG bands, delta (1 - 4.5 Hz), theta (5 - 7.5 Hz), alpha (8 - 11.5 Hz), low-beta (12 - 19.5 366 
Hz), and high-beta (20 - 30 Hz) was computed. Previous research has shown that the wakefulness-367 
induced changes are particularly pronounced in theta (~4 - 8 Hz) and alpha (~8 - 12 Hz) ranges, as 368 
well as in the theta-to-alpha ratio (TAR)6,7,50. The EEG power and ratio values were transformed by a 369 
base 10 logarithm, to approximate a Gaussian distribution. 370 
 371 
Statistical analyses 372 
Spearman’s rank-correlation coefficients (rs), as well as two-, three- and four-way mixed-373 
model ANOVAs (analyses of variance) for repeated measures were computed. The covariance matrix 374 
applied was first order autoregressive and subjects were considered as random effect. To estimate 375 
the influences of circadian and homeostatic sleep regulatory process34, the effect of time awake was 376 
analyzed by considering the within-subjects’ factors ‘clock time’ (8:00, 11:00, 14:00, 17:00, 20:00, 377 
23:00) and ‘day’ (baseline vs. sleep deprivation day). In 22 participants, the assessments at 17:00 378 
and 20:00 were missing due to neuroimaging59. For the analyses of PVT performance, an additional 379 
factor ‘time on task (TOT)’ (quintiles 1-5) was added. Within each quintile, lapse frequency was 380 
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defined as the percentage of lapse trials and response variability as the standard deviation of the 381 
mean response time. The ANOVAs testing overall effects of sleep loss independently of genotype are 382 
shown in Supplementary Table 1. To assess genetic effects, separate ANOVAs with the following 383 
genotypes were performed: ‘DAT1’ (9R; 10R/10R); ‘DRD2’ (C/C; C/T; T/T); ‘DAT1-DRD2 combined’ 384 
(9R-C/C; 9R-C/T; 9R-T/T; 10R/10R-C/C; 10R/10R-C/T; 10R/10R-T/T). Effect sizes (partial eta squared: 385 
ηp2) were calculated from corresponding ANOVA F-values and degrees of freedom. Effect sizes of 386 
0.0099, 0.0588 and 0.1379 are considered small, moderate and large, respectively53,54. To correct for 387 
multiple comparisons, p-values originating from ANOVAs investigating genetic effects were 388 
corrected by false discovery rate (FDR) correction65. Corrected p-values (qFDR-values) below 0.05 389 
were considered significant; post-hoc analyses were only performed when the respective main 390 
effect and/or interactions of the ANOVA withstood FDR correction. Results of all FDR corrected 391 
ANOVAs containing the factor ‘genotype’ are listed in Supplementary Table 2. Unless otherwise 392 
specified, only significant effects and interactions are mentioned. Following FDR corrected significant 393 
ANOVAs, least significant difference (LSD) post-hoc comparisons were performed.   394 
Signal-to-noise ratios (SNR) were defined as group means (µ) divided by the standard 395 
deviation (σ) of EEG power in a given frequency band: 396 
𝑆𝑆𝑆 = 𝜇
𝜎
 
Following this classification, between-subject SNR was defined as the EEG band-power mean and 397 
standard deviation per session across the 81 subjects: 398 
𝜇𝑏𝑏𝑏𝑏𝑏𝑏𝑏 = 181�𝑎𝑖 = 𝑠𝑠𝑠𝑠𝑠𝑠𝑠1 + 𝑠𝑠𝑠𝑠𝑠𝑠𝑠2 +⋯+ 𝑠𝑠𝑠𝑠𝑠𝑠𝑠141481
𝑖=1
 
𝜎𝑏𝑏𝑏𝑏𝑏𝑏𝑏 = � 181�𝑎𝑖 = �𝑠𝑠𝑠𝑠𝑠𝑠𝑠1 + 𝑠𝑠𝑠𝑠𝑠𝑠𝑠2 +⋯+ 𝑠𝑠𝑠𝑠𝑠𝑠𝑠1414 − 𝜇𝑏𝑏𝑏𝑏𝑏𝑏𝑏�281
𝑖=1
 
On the other hand, within-subject SNR was defined as the EEG band-power mean and standard 399 
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deviation per subject across the 14 sessions: 400 
𝜇𝑏𝑖𝑏ℎ𝑖𝑏 = 114�𝑎𝑖 = 𝑠𝑠𝑠𝑠𝑠𝑠𝑠1 + 𝑠𝑠𝑠𝑠𝑠𝑠𝑠2 +⋯+ 𝑠𝑠𝑠𝑠𝑠𝑠𝑠818114
𝑖=1
 
𝜎𝑏𝑖𝑏ℎ𝑖𝑏 = � 114�𝑎𝑖 = �𝑠𝑠𝑠𝑠𝑠𝑠𝑠1 + 𝑠𝑠𝑠𝑠𝑠𝑠𝑠2 +⋯+ 𝑠𝑠𝑠𝑠𝑠𝑠𝑠8181 − 𝜇𝑏𝑏𝑏𝑏𝑏𝑏𝑏�214
𝑖=1
 
Signal to noise ratios across EEG bands, were compared using paired student t-tests.  401 
Statistical analyses were performed with SAS 9.4 software (SAS Institute, Cary, NC), whereas 402 
PVT performance was assessed using IBM SPSS Statistics 22 (IBM Corp., Armonk, USA). Throughout, 403 
estimated means and standard errors of the respective ANOVAs are presented. For illustrative 404 
purposes, genetically-determined higher dopaminergic signaling (DAT1 10R/10R and DRD2 C/C 405 
genotypes) was illustrated in orange color, intermediate dopaminergic signaling (DRD2 C/T 406 
genotype) in blue color, and lower dopaminergic signaling (DAT1 9R and DRD2 T/T genotypes) in red 407 
color when appropriate.  408 
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Table 1. Demographic characteristics of study participants.  575 
 DRD2 genotypes F2,77 (p) DAT1 genotypes F2,79 (p) 
Weight (kg) 
T/T 70.4 ± 1.81 
0.01 
(0.99) 
9R 69.4 ± 1.48 
0.63 
(0.42) 
C/T 70.6 ± 1.32 
10R/10R 73.7 ± 1.74 C/C 70.4 ± 2.05 
Height (cm) 
T/T 178.6 ± 1.54 
0.42 
(0.66) 
9R 177.9 ± 1.12 
0.08 
(0.78) 
C/T 177.0 ± 1.13 
10R/10R 177.4 ± 1.14 
C/C 178.2 ± 1.75 
BMI (kg/m2) 
T/T 22.0 ± 0.39 
0.50 
(0.69) 
9R 22.1 ± 0.29 
1.98 
(0.16) 
C/T 22.5 ± 0.27 
10R/10R 22.6 ± 0.29 C/C 22.1 ± 0.42 
Age (years) 
T/T 23.5 ± 0.65 
0.97 
(0.39) 
9R 24.3 ± 0.48 
0.07 
(0.79) 
C/T 24.3 ± 0.48 
10R/10R 24.1 ± 0.48 C/C 24.8 ± 0.74 
Alcohol 
consumption 
(drinks/week) 
T/T 3.39 ± 0.61 
0.48 
(0.63) 
9R 3.00 ± 0.44 
0.23 
(0.63) 
C/T 3.27 ± 0.45 
10R/10R 3.30 ± 0.45 C/C 2.56 ± 0.69 
Estimated caffeine 
consumption 
(mg/day) 
T/T 119.1 ± 28.07 
0.45 
(0.65) 
9R 114.7 ± 20.46 
0.81 
(0.37) 
C/T 138.5 ± 20.56 
10R/10R 140.9 ± 20.72 C/C 104.2 ± 31.93 
Habitual sleep 
duration  
(hours) 
T/T 7.15 ± 0.15 
1.49 
(0.24) 
9R 7.31 ± 0.11 
1.11 
(0.29) 
C/T 7.36 ± 0.11 
10R/10R 7.14 ± 0.11 C/C 7.03 ± 0.17 
Daytime Sleepiness 
(ESS) 
T/T 7.32 ± 0.59 
1.91 
(0.16) 
9R 7.31 ± 0.50 
0.70 
(0.40) 
C/T 7.46 ± 0.43 
10R/10R 7.04 ± 0.59 C/C 5.94 ± 0.67 
Trait Anxiety (TAI) 
T/T 34.0 ± 1.65 
0.58 
(0.57) 
9R 35.5 ± 1.39 
0.30 
(0.58) 
C/T 35.9 ± 1.21 
10R/10R 35.0 ± 1.64 C/C 36.48 ± 1.88 
 DRD2 genotypes (p) DAT1 genotypes (p) 
Gender ratio 
(% females) 
T/T 13.6 
(1.00) 
9R 12.2 
(0.75) C/T 14.6 
10R/10R 15.4 C/C 11.8 
 576 
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Demographic variables compared between DRD2 and DAT1 genotypes based on validated self-577 
report questionnaires. Data represent means ± SEM; Statistics originate from one-way ANOVAs and 578 
Fisher’s exact test (gender ratio only). Caffeine consumption per serving was calculated based on 579 
self-reported values64,66. Similarly, as reported in the table, no significant difference between 580 
genotypes were observed in the subsample of 64 individuals (data not shown). TAI: Trait Anxiety 581 
Inventory67; ESS: Epworth Sleepiness Scale68. 582 
  583 
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Figure 1 584 
 585 
Evolution of psychomotor vigilance task (PVT) performance and waking EEG oscillations across 586 
prolonged wakefulness. A & B: Vertical axes (y-axes) on the 3D plots represent attention lapses 587 
(lapse frequency) and response variability (standard deviation of response speed), as a function of 588 
time awake (x-axis) and time-on-task (z-axis). Warmer colors represent higher lapse frequency and 589 
increased response variability. C & D: 2D plots illustrating increased lapse frequency and response 590 
variability by sleep deprivation and increased lapse frequency by time-on-task. E - G: Effects of sleep 591 
deprivation on waking EEG theta activity, alpha activity, and theta/alpha ratio (TAR). The gray 592 
background shows the data included in the statistical analyses, categorized as day 1 (baseline) and 593 
day 2 (sleep deprivation). Stars indicate least significant difference (LSD) between day 1 and day 2 (p 594 
< 0.0001).  595 
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Figure 2 597 
 598 
Figure 2. Effect of 40 hours sustained wakefulness on PVT lapses and subjective sleepiness (Stanford 599 
Sleepiness Scale [SSS]), split by the DAT1-DRD2 combined genotypes. A: Evolution of PVT lapses (y-600 
axis) across time awake (x-axis) and time-on-task (z-axis) split into the most vulnerable DAT1-DRD2 601 
genotypes (10R/10R-C/C, 10R/10R-T/T, 9R-T/T and 9R-C/T; left) compared to the two more resilient 602 
genotypes (10R/10R-C/T and 9R-C/C; right). Warmer colors refers to higher lapse frequency. B-C: 603 
Illustration of the highly significant interaction between the DAT1-DRD2 genotypes and sleep 604 
deprivation for lapses of attention. B: The evolution of lapses from baseline (day 1) to sleep 605 
deprivation (day 2). Significant differences between genotypes were only observed on day 2. C: PVT 606 
lapse frequency on day 2 can be described by a U-shaped curve with an arbitrary horizontal axis split 607 
by the DAT1-DRD2 combined genotypes. D: Illustration of the interaction between the DAT1-DRD2 608 
genotypes and sleep deprivation (qFDR < 0.02) for subjective sleepiness (SSS). Similar to C, the 609 
genotypes are plotted on a U-shaped curve, split by DAT1 genotype. Colors represent the six genetic 610 
groups (orange: DRD2 C/C, blue: DRD2 C/T, red: DRD2 T/T, circles: DAT1 10R/10R, triangles: DAT1 611 
9R) and are identical in panels B through D. Group sizes: DAT1 10R/10R, DRD2 C/C (lapses: n = 7, SSS: 612 
n = 9), DAT1 10R/10R, DRD2 C/T (lapses: n = 14, SSS: n = 18), DAT1 10R/10R, DRD2 T/T (lapses: n = 613 
 26 
11, SSS: n = 13), DAT1 9R, DRD2 C/C (lapses: n = 6, SSS: n = 8), DAT1 9R, DRD2 C/T (lapses: n = 20, 614 
SSS: n = 24), DAT1 9R, DRD2 T/T (lapses: n = 6, SSS: n = 9). Significant post-hoc comparisons are 615 
illustrated by horizontal lines, whereas long vertical lines represent the genetic group investigated. 616 
Stars and p-values represent the least significant difference (LSD) following corresponding ANOVAs. 617 
Triple stars: p < 0.0001, double stars: p < 0.005, single stars: p < 0.02. 618 
  619 
 27 
Figure 3 620 
 621 
Figure 3. Effect of 40 hours prolonged wakefulness on the increase in EEG theta-to-alpha ratio (TAR), 622 
split by DAT1, DRD2, and combined DAT1-DRD2 genotypes, all showing significant genotype x sleep 623 
deprivation interactions (qFDR < 0.02). The portion of the waking EEG recordings with eyes open was 624 
analyzed. (A) and (B) Left: TAR quantified at 3-hour intervals for DAT1 (panel A; 10R/10R: orange, 9R: 625 
red) and DRD2 (panel B; C/C: orange, C/T: blue, T/T: red) genotypes. Right: Change in TAR from day 1 626 
to day 2 in DAT1 and DRD2 genotypes. Statistics revealed a significant effect of sleep deprivation on 627 
TAR, which was stronger in 10R/10R homozygotes than 9R-allele carriers of DAT1 and in DRD2 C/C 628 
homozygotes compared to C/T heterozygotes. (C) Increase in TAR from day 1 to day 2 in combined 629 
DAT1-DRD2 genotype groups. The sleep deprivation-induced increase in TAR is described by a U-630 
 28 
shaped curve with an arbitrary horizontal axis, split by DAT1 genotype. P-values represent the least 631 
significant difference (LSD) following the corresponding ANOVA.  632 
 633 
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Supplementary figure 1.  
 
Illustration of the PVT lapse frequency data included in statistical models. A: PVT attention lapses (y-
axis) as a function of time-on-task (z-axis) and time awake (x-axis). Warmer colors refers to higher lapse 
frequency. B: The relative increase in PVT lapse frequency from baseline to the sleep deprived day split 
by the six DAT1-DRD2 genotypes plotted on a U-shaped curve. The figure resembles the reported 
increase in subjective sleepiness (Fig. 2C).    
 
 
3 
Supplementary table 1. Results of all genotype independent ANOVAs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subscript F values represent numerator and denominator degrees of freedom, respectively. Red values 
are below the standard 5% alpha criteria. 
 
  
  F-
value  
p-
value  
PVT lapses Session F5,544 = 9.41 1.31E-08 
ToT F4,520 = 34.92 7.68E-26 
Day F1,1183 = 536.60 3.44E-98 
Session x ToT F20,279 = 0.70 0.83 
Session x Day F5,544 = 9.87 4.82E-09 
ToT x Day F4,520 = 24.19 2.26E-18 
Session x ToT x Day F20,279 = 1.16 0.29 
    
PVT standard deviation Session F5,734 = 6.89 2.70E-06 
ToT F4,845 = 2.31 5.61E-02 
Day F1,2122 = 259.21 4.10E-55 
Session x ToT F20,390 =0.81 0.71 
Session x Day F5,734 = 2.50 2.96E-02 
ToT x Day F4,845 = 0.87 0.48 
Session x ToT x Day F20,390 = 1.12 0.33 
    
Subjective sleepiness Session F5,567 = 17.73 2.44E-16 
Day F1,218 = 920.00 3.58E-80 
Session x Day F5,555 = 3.41 4.85E-03 
    
Waking EEG – Delta band 
1 - 4.5 Hz 
Session F5,619 = 7.02 2.17E-06 
Day F1,213 = 108.81 7.67E-21 
Session x Day F5,573 = 4.99 1.75E-04 
    
Waking EEG – Theta band 
5 – 7.5 Hz 
Session F5,626 = 8.26 1.44E-07 
Day F1,193 = 233.57 4.56E-35 
Session x Day F5,566 = 9.14 2.22E-08 
    
Waking EEG – Alpha band 
8 – 11.5 Hz 
Session F5,649 = 9.33 1.36E-08 
Day F1,169 = 1.81 0.18 
Session x Day F5,569 = 5.87 2.69E-05 
    
Waking EEG – Theta/Alpha ratio Session F5,636 = 2.14 5.88E-02 
Day F1,164 = 177.14 6.81E-28 
Session x Day F5,556 = 1.71 0.13 
    
Waking EEG – low Beta band 
12-19.5 Hz 
Session F5,598 = 13.65 1.24E-12 
Day F1,207 = 24.62 1.45E-06 
Session x Day F5,556 = 20.72 5.27E-19 
    
Waking EEG – high Beta band 
20-30 Hz 
Session F5,590 = 3.46 4.34E-03 
Day F1,182 = 5.66 1.84E-02 
Session x Day F5,537 = 6.77 3.91E-06 
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Supplementary table 2. Overview and results of all genotype related ANOVAs performed.  
 DAT1 DRD2 DAT1-DRD2 
F-value p-value q-value F-value p-value q-value F-value p-value q-value 
PVT 
lapses Genotype 
F1,134 = 
1.00 0.32 0.57 
F2,135 = 
2.20 0.14 0.24 
F5,128 = 
4.75 5.14E
-4 1.82E-3 
Session F5,533 = 9.32 1.61E
-08 1.06E-07 F5,508 = 7.61 6.64E
-07 3.74E-06 F5,509 = 6.59 5.84E
-6 2.61E-5 
ToT F4,509 = 34.44 1.86E
-25 2.75E-24 F4,503 = 30.79 6.01E
-23 8.38E-22 F4,451 = 25.95 2.22E
-19 2.75E-18 
Day F1,1154 = 530.44 7.17E
-97 1.70E-94 F1,1141 = 502.83 1.46E
-92 1.73E-90 F1,1024 = 432.91 1.82E
-80 1.44E-78 
Genotype x 
Session 
F5,533 = 
0.48 0.79 0.91 
F10,510 = 
2.10 2.32E
-02 6.10E-02 F25,531 = 1.85 7.54E
-3 2.29E-2 
Genotype x 
ToT 
F4,509 = 
0.23 0.92 0.98 
F8,500 = 
0.65 0.73 0.91 
F20,452 = 
0.76 0.76 0.91 
Genotype x 
Day 
F1,1154 = 
0.57 0.45 0.71 
F2,1135 = 
4.82 8.23E
-03 2.44E-02 F1,1023 = 12.01 2.55E
-11 1.95E-10 
Session x ToT F20,271 = 0.69 0.84 0.94 
F20,265 = 
0.77 0.75 0.91 
F20,254 = 
0.76 0.76 0.91 
Session x Day F5,533 = 9.76 6.17E
-09 4.30E-08 F5,508 = 7.60 6.79E
-07 3.74E-06 F5,509 = 6.27 1.17E
-5 5.03E-5 
ToT x Day F4,509 = 23.84 4.31E
-18 4.44E-17 F4,503 = 23.60 6.66E
-18 6.58E-17 F4,451 = 19.04 1.75E
-14 1.49E-13 
Genotype x 
ToT x Day 
F4,509 = 
0.42 0.80 0.91 
F8,500 = 
0.59 0.79 0.91 
F20,452 = 
0.87 0.63 0.86 
Genotype x 
Session x Day 
F5,533 = 
0.32 0.90 0.97 
F10,510 = 
2.06 2.59E
-02 6.74E-02 F25,531 = 1.85 7.75E
-3 2.33E-2 
Genotype x 
Session x ToT 
F20,271 = 
0.32 1.00 1.00 
F40,267 = 
0.38 1.00 1.00 
F100,271 = 
0.36 1.00 1.00 
Session x ToT 
x Day 
F20,271 = 
1.14 0.31 0.56 
F20,265 = 
1.06 0.40 0.66 
F20,254 = 
0.90 0.59 0.81 
Quadrupled 
interaction 
F20,271 = 
0.35 1.00 1.00 
F40,267 = 
0.41 0.99 1.00 
F100,271 = 
0.39 1.00 1.00 
           
PVT 
Standard 
deviation  
 
 
Genotype F1,63 = 0.64 0.43 0.69 
F2,62 = 
0.08 0.92 0.98 
F5,59 = 
0.50 0.78 0.91 
Session F5,713 = 6.90 2.68E
-06 1.32E-05 F5,727 = 8.17 1.62E
-07 9.86E-07 F5,649 = 7.03 2.05E
-06 1.06E-05 
ToT F4,826 = 2.27 6.00E
-02 0.14 F4,851 = 2.24 6.29E
-02 0.14 F4,770 = 2.31 5.61E
-02 0.13 
Day F1,2080 = 258.25 7.21E
-55 2.44E-53 F1,2122 = 233.64 4.05E
-50 1.20E-48 F1,1971 = 219.79 3.20E
-47 8.41E-46 
Genotype x 
Session 
F5,713 = 
2.16 5.68E
-02 0.14 F10,724 = 1.77 6.29E
-02 0.14 F25,669 = 1.72 1.69E
-02 4.70E-2 
Genotype x 
ToT 
F4,826 = 
0.95 0.44 0.70 
F8,845 = 
0.18 0.99 1.00 
F20,769 = 
0.55 0.94 0.99 
Genotype x 
Day 
F1,2080 = 
0.37 0.54 0.78 
F2,2106 = 
0.74 0.48 0.74 
F5,1965 = 
0.77 0.57 0.80 
Session x ToT F20,397 = 0.81 0.71 0.90 
F20,379 = 
0.83 0.68 0.88 
F20,441 = 
0.76 0.76 0.91 
Session x Day F5,713 = 2.47 3.14E
-02 7.99E-02 F5,727 = 1.96 8.30E
-02 0.19 F5,649 = 2.15 5.78E
-02 0.14 
ToT x Day F4,826 = 0.86 0.49 0.74 
F4,851 = 
0.73 0.58 0.80 
F4,770 = 
0.53 0.72 0.90 
Genotype x 
ToT x Day 
F4,826 = 
1.96 9.85E
-02 0.22 F8,845 = 1.43 0.18 0.37 
F20,769 = 
1.18 0.27 0.49 
Genotype x 
Session x Day 
F5,713 = 
2.87 1.41E
-02 3.99E-02 F10,724 = 1.61 9.88E
-02 0.22 F25,669 = 1.91 5.15E
-03 1.61E-2 
Genotype x 
Session x ToT 
F20,397 = 
0.70 0.83 0.94 
F40,387 = 
1.00 0.47 0.73 
F100,436 = 
1.07 0.32 0.57 
Session x ToT 
x Day 
F20,397 = 
1.11 0.33 0.58 
F20,379 = 
1.23 0.22 0.44 
F20,414 = 
1.22 0.23 0.44 
Quadrupled 
interaction 
F20,397 = 
0.580 0.93 0.98 
F40,387 = 
1.17 0.23 0.44 
F100,436 = 
0.94 0.65 0.86 
           
Subjective 
sleepiness Genotype 
F1,80 = 
0.59 0.45 0.70 
F2,78 = 
0.73 0.49 0.74 
F5,74 = 
1.45 0.22 0.42 
Session F5,553 = 17.24 7.24E
-16 6.60E-15 F5,439 = 5.22 4.08E
-04 1.46E-03 F5,507 = 15.75 1.99E
-14 1.63E-13 
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Day F1,213 = 884.54 9.42E
-78 5.58E-76 F1,161 = 587.12 1.66E
-55 6.55E-54 F1,201 = 756.34 5.35E
-70 2.54E-68 
Genotype x 
Session 
F5,553 = 
0.32 0.90 0.97 
F10,439 = 
0.63 0.75 0.91 
F25,508 = 
0.58 0.95 1.00 
Genotype x 
Day 
F1,213 = 
0.47 0.49 0.74 
F2,161 = 
0.63 0.88 0.97 
F5,201 = 
3.51 4.59E
-03 1.45E-02 
Session x Day F5,541 = 3.29 6.12E
-03 1.88E-02 F5,453 = 3.04 1.71E
-02 4.72E-02 F5,502 = 2.52 2.87E
-02 7.39E-02 
Genotype x 
Session x Day 
F5,541 = 
0.16 0.98 1.00 
F10,454 = 
0.44 0.90 0.97 
F25,502 = 
0.48 0.99 1.00 
           
Waking EEG 
Delta band 
1 – 4.5 Hz 
Genotype F1,79 = 0.60 0.44 0.70 
F2,77 = 
1.24 0.30 0.54 
F5,74 = 
0.64 0.67 0.88 
Day F1,209 = 108.42 1.01E
-20 1.33E-19 F1,201 = 98.40 3.88E
-19 4.38E-18 F1,193 = 100.88 2.32E
-19 2.75E-18 
Session F5,612 = 7.08 1.90E
-06 1.00E-05 F5,592 = 6.03 1.85E
-05 7.54E-05 F5,568 = 6.08 1.68E
-05 6.98E-05 
Genotype x 
Day 
F1,209 = 
0.13 0.72 0.90 
F2,202 = 
0.34 0.71 0.90 
F5,193 = 
0.85 0.52 0.75 
Genotype x 
Session 
F5,612 = 
1.00 0.42 0.69 
F10,593 = 
1.09 0.37 0.63 
F25,573 = 
0.97 0.50 0.75 
Session x Day F5,565 = 5.03 1.61E
-04 6.06E-04 F5,547 = 4.21 9.23E
-04 3.17E-03 F5,525 = 4.47 5.31E
-04 1.85E-03 
Genotype x 
Session x Day 
F5,565 = 
1.45 0.21 0.41 
F10,547 = 
0.54 0.86 0.96 
F25,539 = 
0.80 0.75 0.91 
           
Waking EEG 
Theta band 
5 – 7.5 Hz 
Genotype F1,79 = 0.04 0.85 0.95 
F2,77 = 
2.24 0.11 0.24 
F5,74 = 
1.20 0.32 0.57 
Day F1,191 = 233.03 6.26E
-35 1.48E-33 F1,185 = 211.86 1.69E
-32 3.33E-31 F1,180 = 221.20 3.95E
-33 8.51E-32 
Session F5,619= 8.26 1.46E
-07 9.08E-07 F5,601 = 6.51 6.54E
-06 2.87E-05 F5,575 = 6.08 1.67E
-05 6.98E-05 
Genotype x 
Day 
F1,191 = 
0.18 0.68 0.88 
F2,186 = 
1.13 0.33 0.57 
F5,180 = 
1.96 8.68E
-02 0.19 
Genotype x 
Session 
F5,619 = 
0.33 0.90 0.97 
F10,602 = 
0.88 0.56 0.80 
F25,577 = 
0.88 0.64 0.86 
Session x Day F5,559 = 9.17 2.15E
-08 1.38E-07 F5,543 = 6.89 3.01E
-06 1.49E-05 F5,521 = 6.77 3.95E
-06 1.87E-05 
Genotype x 
Session x Day 
F5,559 = 
0.91 0.47 0.73 
F10,544 = 
1.35 0.20 0.40 
F25,523 = 
1.09 0.35 0.60 
           
Waking EEG 
Alpha band 
8 – 11.5 Hz 
Genotype F1,79 = 0.00 0.97 1.00 
F2,77 = 
1.05 0.36 0.61 
F5,74 = 
0.79 0.56 0.80 
Day F1,171 = 2.06 0.15 0.32 
F1,163 = 
5.45 2.08E
-02 5.53E-02 F1,162 = 4.42 3.71E
-02 9.26E-02 
Session F5,638 = 9.39 1.19E
-08 8.09E-08 F5,622 = 7.96 2.78E
-07 1.65E-06 F5,594 = 7.86 3.52E
-07 2.03E-06 
Genotype x 
Day 
F1,171 = 
10.65 1.33E
-03 4.49E-03 F2,164 = 3.01 5.20E
-02 0.13 F5,162 = 3.97 2.02E
-03 6.75E-03 
Genotype x 
Session 
F5,638 = 
0.62 0.69 0.89 
F10,622 = 
0.66 0.77 0.91 
F25,601 = 
0.76 0.79 0.91 
Session x Day F5,561 = 5.97 2.15E
-05 8.62E-05 F5,546 = 5.40 7.33E
-05 2.85E-04 F5,524 = 4.88 2.26E
-04 8.37E-04 
Genotype x 
Session x Day 
F5,561 = 
0.59 0.71 0.90 
F10,546 = 
0.76 0.67 0.88 
F25,528 = 
0.75 0.81 0.92 
           
Waking EEG 
Theta/Alpha 
ratio 
Genotype F1,79 = 0.02 0.89 0.97 
F2,77 = 
0.54 0.59 0.81 
F5,74 = 
0.78 0.57 0.80 
Day F1,166 = 187.57 4.47E
-29 7.06E-28 F1,160 = 196.91 1.10E
-29 1.85E-28 F1,158 = 202.13 4.62E
-30 8.42E-29 
Session F5,629 = 2.19 5.36E
-02 0.13 F5,608 = 1.85 0.10 0.22 
F5,580 = 
1.79 0.11 0.24 
Genotype x 
Day 
F1,166 = 
8.58 3.88E
-03 1.26E-02 F2,160 = 6.14 2.69E
-03 8.85E-03 F5,158 = 5.03 2.62E
-04 9.55E-04 
Genotype x 
Session 
F5,626 = 
0.74 0.59 0.81 
F10,609 = 
1.97 3.45E
-02 8.70E-02 F25,584 = 1.17 0.26 0.48 
Session x Day F5,549 = 1.72 0.13 0.27 
F5,533 = 
2.26 4.76E
-02 0.12 F5,512 = 1.79 0.11 0.24 
Genotype x 
Session x Day 
F5,549 = 
0.45 0.81 0.92 
F10,533 = 
1.34 0.21 0.41 
F5,515 = 
1.07 0.38 0.64 
           
Waking EEG 
Low Beta 
12 – 19.5 Hz 
Genotype F1,79 = 0.43 0.51 0.75 
F2,77 = 
0.57 0.57 0.80 
F5,74 = 
0.88 0.50 0.75 
Day F1,205 = 24.43 1.60E
-06 8.61E-06 F1,198 = 22.37 4.26E
-06 1.98E-05 F1,191 = 22.72 3.69E
-06 1.79E-05 
Session F5,590 = 13.63 1.33E
-12 1.05E-11 F5,573 = 11.60 1.09E
-10 8.06E-10 F5,552 = 10.50 1.21E
-09 8.70E-09 
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q-Values: FDR-corrected p-values. Note: The FRD correction is performed across all three genetic groups 
and therefore takes into account all 237 p-values shown in the table. Subscript F values represent 
numerator and denominator degrees of freedom, respectively. Red values are below the standard 5% 
alpha criteria. 
 
 
Genotype x 
Day 
F1,205 = 
1.77 0.19 0.38 
F2,199 = 
0.68 0.51 0.75 
F5,192 = 
0.87 0.50 0.75 
Genotype x 
Session 
F5,590 = 
1.18 0.32 0.57 
F10,574 = 
0.68 0.74 0.91 
F25,557 = 
0.80 0.74 0.91 
Session x Day F5,549 = 20.74 5.26E
-19 5.67E-18 F5,533 = 17.42 5.50E
-16 5.21E-15 F5,513 = 17.09 1.20E
-15 1.05E-14 
Genotype x 
Session x Day 
F5,549 = 
0.65 0.66 0.88 
F10,534 = 
0.51 0.88 0.97 
F25,517 = 
0.49 0.98 1.00 
           
Waking EEG 
High Beta 
20 – 30 Hz 
 
Genotype F1,79 = 0.61 0.44 0.70 
F2,77 = 
0.44 0.65 0.86 
F5,74 = 
1.04 0.40 0.66 
Day F1,178 = 5.65 1.85E
-02 4.98E-02 F1,172 = 6.88 9.49E
-03 2.78E-02 F1,165 = 6.57 1.13E
-02 3.25E-02 
Session F5,582 = 3.43 4.58E
-03 1.45E-02 F5,568 = 2.94 1.25E
-02 3.56E-02 F5,547 = 2.76 1.79E
-02 4.87E-02 
Genotype x 
Day 
F1,178 = 
0.79 0.38 0.64 
F2,172 = 
0.90 0.41 0.67 
F5,154 = 
0.47 0.80 0.91 
Genotype x 
Session 
F5,582 = 
0.32 0.90 0.97 
F10,569 = 
1.20 0.29 0.54 
F25,551 = 
0.78 0.78 0.91 
Session x Day F5,529 = 6.69 4.64E
-06 2.11E-05 F5,515 = 5.74 3.65E
-05 1.44E-04 F5,495 = 5.23 1.08E
-04 4.13E-04 
Genotype x 
Session x Day 
F5,529 = 
0.53 0.76 0.91 
F10,516 = 
1.29 0.23 0.44 
F25,497 = 
0.87 0.65 0.86 
